What is Madrigal Pharmaceuticals Inc's share price today?
Madrigal Pharmaceuticals Inc (MDGL) share price today is $516.87 as of August 22, 2026 at 1:30 AM IST. The stock touched a day high of $530.65 and a day low of $515.28.What exchange does Madrigal Pharmaceuticals Inc stock trade on, and under what ticker symbol?
Madrigal Pharmaceuticals Inc stock trades on NASDAQ under the ticker symbol MDGL.What is Madrigal Pharmaceuticals Inc's market capitalization?
Madrigal Pharmaceuticals Inc's market capitalization is $12.47B as of August 22, 2026 at 1:30 AM IST.What is Madrigal Pharmaceuticals Inc's price-to-earnings (P/E) ratio?
Madrigal Pharmaceuticals Inc's price-to-earnings (P/E) ratio is N/A as of August 21, 2026.What is Madrigal Pharmaceuticals Inc's price-to-book (P/B) ratio?
Madrigal Pharmaceuticals Inc's price-to-book (P/B) ratio is 23.13 as of August 21, 2026.Can Indian investors buy Madrigal Pharmaceuticals Inc shares?
Yes, You can buy Madrigal Pharmaceuticals Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in Madrigal Pharmaceuticals Inc shares from India?
Indian investors can buy Madrigal Pharmaceuticals Inc shares in three steps: 1. Search Madrigal Pharmaceuticals Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from Madrigal Pharmaceuticals Inc shares for Indian investors?
Since Madrigal Pharmaceuticals Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in Madrigal Pharmaceuticals Inc shares via Tickertape?
Indian investors can start investing in Madrigal Pharmaceuticals Inc (MDGL) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0193 shares at the current price of $516.87.
$
₹
$516.870.42% (-2.21)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
1D
1W
1M
1Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
—
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
23.13
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$-14.42
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
0
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
-25.31%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
—
Analyst Ratings & ForecastAnalyst Ratings & Forecast
Analyst Ratings & Forecast
Analyst Ratings & Forecast
Based on 15 analysts' reports
Buy13 analysts
Hold1 analyst
Sell1 analyst
Analysts expect a +31.22% price upside over the next year
Current Price$516.87
Target Price$678.06
Company Profile
Peers
Peers
ABBV
P/E Ratio
73.06
73.06
1Y Return
25.87%
25.87%
Buy Reco %
57.14
57.14
AMGN
P/E Ratio
26.37
26.37
1Y Return
50.81%
50.81%
Buy Reco %
46.87
46.87
P/E Ratio
—
—
1Y Return
26.68%
26.68%
Buy Reco %
63.33
63.33
P/E Ratio
30.77
30.77
1Y Return
37.88%
37.88%
Buy Reco %
52.94
52.94
P/E Ratio
20.03
20.03
1Y Return
39.6%
39.6%
Buy Reco %
76.00
76.00
Peers & Comparison
Peers & Comparison
HealthcareBiotechnology
Valuation
Returns
Forecast
| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| Madrigal Pharmaceuticals Inc | - | 23.13 | 0 |
| AbbVie Inc | 73.06 | 50.45 | 0.42 |
| Amgen Inc | 26.37 | 19.68 | 2.23 |
Price Comparison
Price Comparison
1 Month
1 Year
5 Years
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
| Financial Year | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 14.63 | 62.17 | 103.32 | 137.25 | 212.80 | 287.26 | 321.08 | 311.33 | 364.25 |
| Gross Profit | -0.16 | 14 | 60.02 | 99.87 | 132.73 | 203.73 | 269.14 | 296.63 | 284.49 | 324.24 |
| Net Income | -147.54 | -151.97 | -106.96 | -59.41 | -73.23 | -42.28 | -114.19 | -58.57 | -94.39 | -57.93 |
| Net Profit Margin | - | -1038.19% | -172.03% | -57.50% | -53.36% | -19.86% | -39.75% | -18.24% | -30.31% | -15.90% |